Loading
A phase 2 trial of Plitidepsin in Liposarcoma, run by Institut Bergonié, recorded as terminated on the registry.
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial is a phase 2 interventional study registered as NCT01876043 by Institut Bergonié, with 24 participants recorded, started 2012-02 and due to reach its primary completion in 2015-04. Interventions recorded: plitidepsin. Conditions recorded: Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma.
Linked to the drug Plitidepsin because the registry names it among its interventions and Liposarcoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
24 enrolled.
95% CI 20.9 to 60.1; Figures from the ClinicalTrials.gov results section (first posted 2019-11-12), not from a publication
Source95% CI 1.4 to 2.6; Figures from the ClinicalTrials.gov results section (first posted 2019-11-12), not from a publication
SourceShares Plitidepsin and the tag pipeline.
Shares Plitidepsin and the tag pipeline.
Shares Liposarcoma and the tag pipeline.
Shares Liposarcoma and the tag pipeline.